Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.
Lotte L HoeijmakersIrene L M ReijersChristian U BlankPublished in: Cancer discovery (2023)
In accordance with the increasing rate of therapy development, the need for biomarker-driven personalized treatments grows. The current landscape of neoadjuvant treatment and biomarker development in stage III melanoma can function as a poster child for these personalized treatments in other tumors, assisting in the development of new biomarker-based neoadjuvant trials. This will contribute to personalized benefit-risk predictions to identify the most beneficial treatment for each patient.